Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 17.68 USD 0.4% Market Closed
Market Cap: 895.8m USD

Wall Street
Price Targets

TBPH Price Targets Summary
Theravance Biopharma Inc

Wall Street analysts forecast TBPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TBPH is 27.25 USD with a low forecast of 13.13 USD and a high forecast of 44.1 USD.

Lowest
Price Target
13.13 USD
26% Downside
Average
Price Target
27.25 USD
54% Upside
Highest
Price Target
44.1 USD
149% Upside
Theravance Biopharma Inc Competitors:
Price Targets
600196
Shanghai Fosun Pharmaceutical Group Co Ltd
34% Upside
600267
Zhejiang Hisun Pharmaceutical Co Ltd
31% Downside
1681
Consun Pharmaceutical Group Ltd
30% Upside
605507
Guobang Pharma Ltd
25% Upside

Revenue
Forecast

Revenue Estimate
Theravance Biopharma Inc

For the last 12 years the compound annual growth rate for Theravance Biopharma Inc's revenue is -6%. The projected CAGR for the next 3 years is 24%.

-6%
Past Growth
24%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Theravance Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Theravance Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TBPH's stock price target?
Price Target
27.25 USD

According to Wall Street analysts, the average 1-year price target for TBPH is 27.25 USD with a low forecast of 13.13 USD and a high forecast of 44.1 USD.

What is Theravance Biopharma Inc's Revenue forecast?
Projected CAGR
24%

For the last 12 years the compound annual growth rate for Theravance Biopharma Inc's revenue is -6%. The projected CAGR for the next 3 years is 24%.

Back to Top